Related Experiment Video

Updated: Jul 7, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

[Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic

P Ströbel1, S Knop, H Einsele

  • 1Institut für Pathologie, Universitätsklinikum Mannheim der Universität Heidelberg.

Verhandlungen Der Deutschen Gesellschaft Fur Pathologie
|March 5, 2008
PubMed
Abstract

Insights

Targeted therapies show promise for thymic cancers. Research on c-Kit and EGFR in thymomas and thymic squamous cell carcinomas (TSCC) suggests potential for treatments like Cetuximab in subsets of patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Malignant thymic epithelial tumors (thymomas and thymic carcinomas) often resist current treatments, necessitating exploration of second-line therapies.
  • Identifying molecular targets is crucial for improving outcomes in these rare cancers.

Purpose of the Study:

  • To investigate alterations in receptor tyrosine kinases c-Kit and epidermal growth factor receptor (EGFR) in malignant thymomas and thymic squamous cell carcinomas (TSCC).
  • To assess the functional relevance of these alterations for tumor cell behavior and potential therapeutic responses.

Main Methods:

  • Genomic sequencing and ex vivo explant cell cultures were employed for analysis.
  • Focus was placed on c-Kit and EGFR alterations in malignant thymomas and TSCC.

Main Results:

  • c-Kit was overexpressed in TSCC but not thymomas; mutations were infrequent (10%).
  • EGFR was strongly expressed in 70% of thymomas and 35% of TSCC, with no observed mutations.
  • In vitro studies indicated Cetuximab efficacy in a subset of tumors, highlighting variable responses.

Conclusions:

  • Findings may predict therapeutic responses to emerging targeted treatments for thymic malignancies.
  • The study provides insights for developing novel treatment strategies for thymomas and thymic carcinomas.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...